Adenosine Deaminase (ADA) Antibody
780€ (1 ml)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Adenosine Deaminase (ADA) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx171081
tested applications
WB, IHC, IF/ICC
Description
This product is currently in development. The lead time for this product may be several months. Please contact us at
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Adenosine Deaminase (ADA) |
| Host | Mouse |
| Reactivity | Human |
| Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Purification | Purified by Protein A and Protein G affinity chromatography. |
| Size 1 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Please enquire. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | Adenosine aminohydrolase |
| Background | Antibody anti-ADA |
| Status | RUO |
Descripción
Adenosine deaminase (ADA) is an enzyme crucial in purine metabolism, responsible for catalyzing the irreversible deamination of adenosine and deoxyadenosine to inosine and deoxyinosine, respectively. ADA is predominantly found in lymphocytes, with high activity in tissues such as the thymus, spleen, and bone marrow. It is vital for the development and maintenance of the immune system, as its deficiency leads to the accumulation of toxic purine metabolites, which impair DNA synthesis and lymphocyte survival. Mutations in the ADA gene result in severe combined immunodeficiency (SCID), characterized by a lack of functional T, B, and NK cells. ADA is also widely studied as a marker of immune activation and inflammation in conditions like tuberculosis and rheumatoid arthritis. Therapeutic interventions for ADA deficiency include enzyme replacement therapy and gene therapy, both of which aim to restore immune function.
Related Products
Human ADA(Adenosine deaminase) ELISA Kit
Ver Producto
Mouse ADA(Adenosine deaminase) ELISA Kit
Ver Producto